Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
William J. Gradishar(Cancer Institute (WIA)), Benjamin O. Anderson, Ronald Balassanian, Sarah L. Blair(Barnes-Jewish Hospital), Harold J. Burstein(Cancer Institute (WIA)), Amy Cyr, Anthony Elias(Cancer Institute (WIA)), William B. Farrar(Barnes-Jewish Hospital), Andres Forero, Sharon H. Giordano(Cancer Institute (WIA)), Matthew P. Goetz(Cancer Institute (WIA)), Lori J. Goldstein(Cancer Institute (WIA)), Steven J. Isakoff(Cancer Institute (WIA)), Janice A. Lyons, P. Kelly Marcom, Ingrid A. Mayer(Cancer Institute (WIA)), Beryl McCormick, Meena S. Moran(Cleveland Clinic), Ruth O’Regan(Cancer Institute (WIA)), Sameer A. Patel, Lori J. Pierce(Cleveland Clinic), Elizabeth Reed(Cancer Institute (WIA)), Kilian Salerno(Cleveland Clinic), Lee S. Schwartzberg(Cancer Institute (WIA)), Amy M. Sitapati, Karen L. Smith(Cancer Institute (WIA)), Mary Lou Smith, Hatem Soliman(Cancer Institute (WIA)), George Somlo(Cancer Institute (WIA)), Melinda L. Telli(Cancer Institute (WIA)), John H. Ward(Cancer Institute (WIA)), Rashmi Kumar, Dorothy A. Shead
Cited by 1,616Open Access
Abstract
Ductal carcinoma in situ (DCIS) of the breast represents a heterogeneous group of neoplastic lesions in the breast ducts. The goal for management of DCIS is to prevent the development of invasive breast cancer. This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.
Related Papers
No related papers found
Powered by citation graph analysis